16. Pro Forma Information – Vitro Acquisition

Had the Vitro Acquisition, described in Note 15 and the related financing described in Note 8, occurred at the beginning of each respective period, unaudited pro forma consolidated net sales, earnings from continuing operations and earnings from continuing operations per share of common stock (diluted) would have been as follows:


		Three months ended September 30, 2015
		As		Acquisition		Financing		Pro Forma
		Reported		Adjustments		Adjustments		As Adjusted

Net sales	$	1,566	$	143	$	—	$	1,709

Earnings from continuing operations attributable to the Company		18		18		(11)		25

Diluted earnings per share from continuing operations		0.11						0.15


		Nine months ended September 30, 2015
		As		Acquisition		Financing		Pro Forma
		Reported		Adjustments		Adjustments		As Adjusted

Net sales	$	4,530	$	574	$	—	$	5,104

Earnings from continuing operations attributable to the Company		131		79		(46)		164

Diluted earnings per share from continuing operations		0.81						1.01


		Three months ended September 30, 2014
		As		Acquisition		Financing		Pro Forma
		Reported		Adjustments		Adjustments		As Adjusted

Net sales	$	1,745	$	224	$	—	$	1,969

Earnings from continuing operations attributable to the Company		61		25		(18)		68

Diluted earnings per share from continuing operations		0.37						0.41


		Nine months ended September 30, 2014
		As		Acquisition		Financing		Pro Forma
		Reported		Adjustments		Adjustments		As Adjusted

Net sales	$	5,181	$	651	$	—	$	5,832

Earnings from continuing operations attributable to the Company		297		64		(53)		308

Diluted earnings per share from continuing operations		1.79						1.85